Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Скачать или смотреть MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma

  • International Myeloma Foundation
  • 2025-03-13
  • 567
MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma
myelomamultiple myelomacancerbone marrow cancercancer treatmentcancer researchbone diseasedr brian duriebone marrowmultiple myeloma cancerbone cancerbone marrow diseaseblood cancerblood plasma cancerblood cancer researchcancer research foundationmyeloma treatmentblood cancer treatmentmgusrelapserefractoryinternational myeloma foundationmultiple myeloma foundationcure trialsmyeloma cure trialsBlack Swan Research
  • ok logo

Скачать MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

  • Информация по загрузке:

Cкачать музыку MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma

Elranatamab (ELRA), a bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells, showed promising results in the MagnetisMM-3 trial for relapsed or refractory multiple myeloma (RRMM). The study assessed its efficacy and safety over an extended period, including outcomes after transitioning to dosing once every 4 weeks (Q4W).

Key Points:
ELRA induced deep and durable responses in BCMA-naive RRMM patients.
Primary endpoint: Objective Response Rate (ORR) was 61.0%, with 37.4% achieving complete response or better.
Median duration of response (DOR) not reached; 66.9% probability of maintaining response at 24 months.
Safety profile: Reduced dosing frequency to Q4W showed manageable adverse events (AEs), including infections and hematologic disorders.
Conclusion: ELRA demonstrates sustained efficacy and safety in heavily pretreated RRMM patients, supporting Q4W dosing as a potential safety improvement.

Authors:
H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
X/Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52...

Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.

Комментарии

Информация по комментариям в разработке

Похожие видео

  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]